Craig A Steger (pictured) has joined Outcome Capital as a Senior Advisor in the firm’s Boston area-based life sciences practice, bolstering the firm’s expertise in the molecular diagnostics and biotechnology sectors.
A business leader with extensive global experience, Steger has been part of several successful molecular diagnostic start-ups through their eventual acquisitions. Steger joins Outcome from Forge 4ward, a life science and diagnostic consulting firm, where he has been working with clients to develop their commercial strategy and build value both in the US and globally. He has held various executive positions from start-up companies through large, well-established international corporations. His success in building commercially viable and sustainable enterprises has led to the completion of several successful acquisitions over the past several years including Caliper Life Sciences, HandyLab and BioHelix. Key successes also include developing and launching new businesses at Fisher Healthcare and Becton Dickinson. Steger’s scientific background and business experience spans sales, marketing, business development, licensing, strategic partnerships and operations. Steger holds a Bachelor of Science from the University of Wisconsin and a Master of Science from Yale University.
“I love helping life science companies grow, and at Outcome I am able to accomplish this using the firm’s unique market-driven strategy approach that aligns businesses with sector dynamics – an approach that resonates well with both my experience and passion,” says Steger. “It’s never just about a financial transaction – we’re in the trenches with our clients getting a deep understanding of their value proposition before identifying the most strategic path forward toward optimal value creation.”
Dr Oded Ben-Joseph, Managing Director at Outcome Capital commented: “As the life sciences market has matured, we have experienced considerable growth from mid- to growth-stage companies looking for sound strategies for mergers and acquisitions, private debt and equity placement, and other strategic and corporate finance advisory services. Unique among investment banking firms, our strategic approach to value enhancement relies on significant corporate and operational experience, and Craig’s experience nicely complements our growing life sciences team and bolsters our expertise in molecular diagnostics and biotechnology.”
